Particle.news
Download on the App Store
6 ARTICLES
·
last mo.

Landmark Trial Begins in France Over Glyphosate's Alleged Role in Birth Defects

The Grataloup family confronts Bayer-Monsanto in court, seeking accountability for severe malformations they link to prenatal glyphosate exposure.

Sabine Grataloup et son fils, Théo, né avec de graves malformations du larynx, de l’œsophage et du système respiratoire.
Théo Grataloup, avec ses parents Sabine et Thomas, le 5 octobre 2017 à Moidieu-Detourbe.
AFP - Bayer
Image

Overview

  • Théo Grataloup, born in 2007 with severe congenital malformations, has undergone over 50 surgeries to address issues with his larynx, esophagus, and respiratory system.
  • The family alleges that glyphosate exposure during Sabine Grataloup's early pregnancy, via the herbicide Glyper, caused Théo's malformations.
  • This trial, taking place in Vienne, France, on April 3, 2025, is the first globally to address congenital malformations allegedly linked to glyphosate exposure.
  • The case highlights the lack of scientific consensus on glyphosate's health effects, raising broader questions about corporate accountability and public health safety.
  • Bayer-Monsanto faces potential precedent-setting legal consequences as the court examines the alleged link between glyphosate and birth defects.